NAPSR News: FDA Approves GSK’s New Asthma Medicine Arnuity™ Ellipta®

GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.
Spread the Word
Listed Under

* Napsr
* Napsrx
* Naprx
* CNPR Certification Program
* Pharmaceutical Sales

* Health
* Medical

* Washington - District of Columbia - US

WASHINGTON - Aug. 21, 2014 - PRLog -- GlaxoSmithKline (GSK) has received FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder) to treat asthma. The prophylactic therapy is a once-daily inhaled corticosteroid (ICS) and should only be used by patients aged 12 years and older.

The dosage amount of Arnuity Ellipta is 100mcg and 200mcg and is administered once daily via Ellipta – GlaxoSmithKline’s dry powder inhaler that is also used for a variety of approved medicines in the company’s respiratory portfolio. According to the company, Arnuity Ellipta’s efficacy and safety have been assessed in more than 3,600 patients with asthma.

Darrell Baker, Senior Vice President & Head, GSK Global Respiratory Franchise, said, “The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients.”

Asthma affects people of all ages and according to the National Heart, lung and Blood Institute it is estimated that more than 25 million people in the United States are known to have this condition. The approval of Arnuity Ellipta in the United Sates is expected to boost GlaxoSmithKline’s presence in the US respiratory market.

With such industry leaders paving the way with new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at

Email:*** Email Verified
Tags:Napsr, Napsrx, Naprx, CNPR Certification Program, Pharmaceutical Sales
Industry:Health, Medical
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Daily News
Weekly News

Like PRLog?
Click to Share